相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D. Catovsky et al.
LANCET (2007)
Phase I trial of g3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: A Children's Oncology Group study
Susan R. Rheingold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
BF Eichhorst et al.
BLOOD (2006)
Antisense strategies for oncogene inactivation
CA Stein et al.
SEMINARS IN ONCOLOGY (2005)
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia
GA Calin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia
SM O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
miR-15 and miR-16 induce apoptosis by targeting BCL2
A Cimmino et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells
M Burger et al.
BLOOD (2005)
Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α
M Nishio et al.
BLOOD (2005)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Expression of the NF-κB targets BCL2 and BIRCS/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively
L Tracey et al.
JOURNAL OF PATHOLOGY (2005)
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer
AW Tolcher et al.
CLINICAL CANCER RESEARCH (2005)
Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation
P Menendez et al.
LEUKEMIA (2004)
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
G Marcucci et al.
BLOOD (2003)
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
JC Byrd et al.
BLOOD (2003)
The triterpenoid CDDO induces apoptosis in refractory CLL B cells
IM Pedersen et al.
BLOOD (2002)
Oblimersen bcl-2 antisense: Facilitating apoptosis in anticancer treatment
RJ Klasa et al.
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2002)
Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL)
S Faderl et al.
LEUKEMIA (2002)
Expression of bcl-2 and bax in cells isolated from B-chronic lymphocytic leukemia patients at different stages of the disease
A Aviram et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2000)
分享论文
